

Mediclinic Intl plc - Director/PDMR Shareholding

July 23, 2021

RNS Number : 3216G
Mediclinic International plc
23 July 2021

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")

23 July 2021

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 21 July 2021, Jurgens Myburgh, Group Chief Financial Officer, acquired 4 000 shares in the Company at a price of ZAR57.06 per share. Subsequently, on 22 July 2021, Dr Ronnie van der Merwe, Group Chief Executive Officer, acquired 10 000 shares in the Company at a price of ZAR57.02 per share.

These purchases were made following the vesting on 20 July 2021 of awards made under the Company's Short Term Incentive scheme, which were settled in cash in accordance with the remuneration policy that applied at the time the awards were granted, as set out in the announcement issued on 21 July 2021 (RNS number 9636F). Consistent with that policy, both directors have applied proceeds from the vesting towards purchasing shares in the Company to continue building up their shareholding towards their minimum shareholding guidelines under the current remuneration policy.

Following these transactions, Jurgens Myburgh and Ronnie van der Merwe now own a total of 94 500 and 61 630 shares, respectively, in Mediclinic.

The following notifications are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / persons closely associated with them ("PCA")	
a)	Name	Carel Aron van der Merwe
2.	Reason for the notification	

a)	Position / status	Group Chief Executive Officer	
b)	Initial notification / amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88	
b)	Nature of the transaction	Purchase of shares	
c)	Price(s) and volume(s)	Price(s) per share ZAR57.02	Volume(s) 10 000
d)	Aggregated information Aggregated volume Price	10 000 ZAR57.02 per share	
e)	Date of the transaction	22 July 2021	
f)	Place of the transaction	Johannesburg Stock Exchange	

1.	Details of PDMR / persons closely associated with them ("PCA")		
a)	Name	Mr Petrus Jurgens Myburgh	
2.	Reason for the notification		
a)	Position / status	Group Chief Financial Officer	
b)	Initial notification / amendment	Initial notification	

3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88	
b)	Nature of the transaction	Purchase of shares	
c)	Price(s) and volume(s)	Price(s) per share	Volume(s)
		ZAR57.06	2 524
		ZAR57.06	1 476
d)	Aggregated information Aggregated volume Price	4 000 ZAR57.06 per share	
e)	Date of the transaction	21 July 2021	
f)	Place of the transaction	Johannesburg Stock Exchange	

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden

operated 17 hospitals and four day case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.

The Company's primary listing is on the London Stock Exchange ("**LSE**") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet
+44 (0)333 300 1930

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries

FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBBGDRIXDDGBX